On Jun 30, 2021 Mammogen closed a Seed round and raised $2,000,000. The round was oversubscribed by a diverse group of high-net-worth investors, comprising 52% women, members of the LGBTQ+ community, and veterans from the US Armed Forces, according to the company.

About the company: Mammogen is located in California, United States and is is a female-led biotechnology company. Mammogen improves the detection, diagnosis, and treatment of breast cancer.  The company’s device is a non-invasive screening solution particularly for the under-40 population who aren’t eligible for annual mammography, and the 55+ population who are only recommended for mammography every other year. The device is enabling doctors to get more women screened earlier and arm clinicians with actionable insights about their patients. “Mammogen’s technology will provide regular and reliable screening and diagnostic tools for tens of millions of women who are grossly underserved by current standards of care”

Company website: www.mammogen.bio/